A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma.
about
Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)Extracellular Matrix, a Hard Player in AngiogenesisRecent advances in the pathobiology and management of Kasabach-Merritt phenomenon.The clinical features, treatment, and prognosis of primary mediastinal malignant melanoma: A case report.Anti-tumor effect of a novel soluble recombinant human endostatin: administered as a single agent or in combination with chemotherapy agents in mouse tumor models.Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trialsRecombinant human endostatin enhances the radioresponse in esophageal squamous cell carcinoma by normalizing tumor vasculature and reducing hypoxiaEndostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications.Pharmacokinetics of PEGylated recombinant human endostatin (M2ES) in ratsA Network Meta-Analysis of Short and Long-Term Efficacy of Targeted Therapy With Single or Double-Drug Regimens in the Treatment of Stage III/IV Malignant Melanoma Based on 16 Randomized Controlled Trials.Comparisons of biophysical properties and bioactivities of mono-PEGylated endostatin and an endostatin analog.Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancerMatricryptins and matrikines: biologically active fragments of the extracellular matrix.Endostatin combined with radiotherapy suppresses vasculogenic mimicry formation through inhibition of epithelial-mesenchymal transition in esophageal cancer.Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma.Dacarbazine combined targeted therapy versus dacarbazine alone in patients with malignant melanoma: a meta-analysis.Case report of a KIT-mutated melanoma patient with an excellent response to apatinib and temozolomide combination therapy.Endostar in combination with postoperative adjuvant chemotherapy prolongs the disease free survival of stage IIIA NSCLC patients with high VEGF expression.Antiangiogenic effects of recombinant human endostatin in lung cancers.Preparation of endostatin-loaded chitosan nanoparticles and evaluation of the antitumor effect of such nanoparticles on the Lewis lung cancer model.Anorectal mucosal melanoma.A Retrospective Study to Compare Five Induction Chemotherapy Regimens Prior to Radiotherapy in the Reduction of Regional Lymph Node Size in Patients with Nasopharyngeal Carcinoma.Vemurafenib in Chinese patients with BRAFV600 mutation-positive unresectable or metastatic melanoma: an open-label, multicenter phase I study.Tumor angiogenesis and anti-angiogenic gene therapy for cancer.Apatinib mesylate tablet in the treatment of advanced malignant melanoma
P2860
Q26770492-C65F50AD-44E4-499E-BDF0-CA45CEE5C863Q28072886-3ABB89D6-96AE-4ED8-AAAF-DDDBCA21022DQ33423967-36D34592-02E2-4773-90F8-9CF8695E88D4Q33627022-BFF0FA08-F0DB-4A2A-A845-DA97E9F6AD11Q34208826-9027E2D9-25F7-4BCB-8140-B26C6CA8EA3AQ35645254-0AE603BD-D458-45F4-AC28-6875B7401F6BQ36100135-23E39859-C7AE-474D-8092-09B98E1CDCAFQ36220259-A16834C6-3B07-40D2-823A-91B670A370ACQ36287721-854DC7D3-DCA2-4F90-ADCE-A30DFB2BF00EQ36409040-BCA59203-BF4D-464F-9C6D-EBBB5C1587A2Q36485789-EDC170D8-3DEA-43B9-8FA6-65A229CFF5C6Q37116858-C45139EE-AADB-44AB-AD15-E8788B06992BQ38210749-B36B9C9D-72B0-4D55-AB86-056B71FEBE72Q38824047-B5CC39F0-0746-406C-9F1F-3466971033AEQ39978774-4D0D667A-9BC4-4D00-98F8-54E7CEB29881Q41696382-9172E4BB-440A-42AC-8353-4280DE788E5DQ42736022-DA7A8DBB-17FC-42EB-B0B5-3F66168788E3Q45124523-69375099-741E-4444-8F56-4EC37512AAC1Q47370386-DD1C9986-75B7-4F81-B05E-EA2ABF85E4FCQ51150732-232DB366-2995-4B6A-8CDB-28E6FAF7922DQ52680468-8A215C8B-9AC1-47C9-87BA-1972AE5C0A66Q54968036-BC8FACF4-21F1-40F2-B3E8-7369BFDD7AAFQ54979813-3F167268-1A8E-420C-839E-459464F78B7FQ55385227-AE1C97D5-2BCF-47ED-BF03-CF3D2EE16FA7Q58781253-BB689033-E3CB-42C4-9825-FDAD6998CC21
P2860
A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
A phase II, randomized, double ...... ents with metastatic melanoma.
@en
type
label
A phase II, randomized, double ...... ents with metastatic melanoma.
@en
prefLabel
A phase II, randomized, double ...... ents with metastatic melanoma.
@en
P2093
P2860
P921
P356
P1433
P1476
A phase II, randomized, double ...... ents with metastatic melanoma.
@en
P2093
Chuanliang Cui
Kangsheng Gu
Shukui Qin
Tongyu Lin
P2860
P304
P356
10.1038/MT.2013.79
P577
2013-05-14T00:00:00Z